Dr. Flaherty on the COLUMBUS Trial Updates in Melanoma

Dr. Flaherty on the COLUMBUS Trial Updates in Melanoma

Publication date: Jul 23, 2019

Keith T. Flaherty, MD, director, Henri and Belinda Termeer Center for Targeted Therapy, Massachusetts General Hospital Cancer Center, and professor of medicine, Harvard Medical School, discusses an update on overall survival (OS) in COLUMBUS, a randomized phase III trial of encorafenib (Braftovi) plus binimetinib (Mektovi) versus vemurafenib (Zelboraf) or encorafenib in patients with BRAF V600-mutant melanoma.

Website: https://www.onclive.com

Twitter: https://twitter.com/OncLive

Facebook: https://www.facebook.com/OncLive/

LinkedIn: https://www.linkedin.com/company/onclive/

Concepts Keywords
Affidavit Medicine
Beer Clinical medicine
Belinda Cancer
BRAF B-Raf inhibitor
FDA Cancer treatments
Giraffe Genentech
Grafted Benzamides
Harvard Sulfonamides
Inhibitor Vemurafenib
Kobe Binimetinib
LinkedIn Encorafenib
Massachusetts General Hospital Melanoma
Medicine
Melanoma
Monotherapy
Mutant
Overtime
Phase III
Vemurafenib

Semantics

Type Source Name
disease MESH Melanoma
disease DOID Melanoma
pathway BSID Melanoma
disease MESH Cancer
disease DOID Cancer
drug DRUGBANK Encorafenib
drug DRUGBANK Binimetinib
drug DRUGBANK Vemurafenib
gene UNIPROT BRAF
drug DRUGBANK Coenzyme M

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *